Relcovaptan

Drug Profile

Relcovaptan

Alternative Names: SR 49059

Latest Information Update: 03 Oct 2006

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antihormones; Indoles; Pyrrolidines; Vasodilators
  • Mechanism of Action Vasopressin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Coronary spasm; Dysmenorrhoea; Heart failure; Hypertension; Preterm labour; Small cell lung cancer

Most Recent Events

  • 10 Sep 2003 Discontinued - Preclinical for Coronary spasm in France (PO)
  • 10 Sep 2003 Discontinued - Phase-II for Small cell lung cancer in France (PO)
  • 04 Sep 2001 Discontinued-Clinical for Preterm labour in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top